Avellino

Biotechnology ResearchCalifornia, United States51-200 Employees

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

Sign up for free to view info

Email Format Employee directory